- Ownership
-
Nektar Therapeutics Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Friday, April 25th, 2025 | 2023 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 0 | 1,030,361 | 93,465 | 3,135,576 |
| Friday, April 25th, 2025 | 2022 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 4,032,255 | 650,754 | 98,821 | 11,275,830 |
| Friday, April 25th, 2025 | 2024 | Mark A. Wilson Chief Legal Officer | 540,000 | 0 | 0 | 336,600 | 21,697 | 1,297,327 |
| Friday, April 25th, 2025 | 2024 | Sandra Gardiner Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 460,850 | 460,850 |
| Friday, April 25th, 2025 | 2023 | Sandra Gardiner Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 376,300 | 376,300 |
| Friday, April 25th, 2025 | 2022 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 1,325,673 | 253,256 | 289,625 | 4,350,480 |
| Friday, April 25th, 2025 | 2023 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 0 | 400,989 | 490,585 | 1,773,364 |
| Friday, April 25th, 2025 | 2024 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 0 | 431,885 | 15,825 | 1,611,620 |
| Friday, April 25th, 2025 | 2022 | Mark A. Wilson Chief Legal Officer | 527,500 | 0 | 1,629,478 | 194,400 | 28,093 | 4,565,465 |
| Friday, April 25th, 2025 | 2023 | Mark A. Wilson Chief Legal Officer | 540,000 | 0 | 0 | 307,800 | 20,878 | 1,100,468 |
| Friday, April 25th, 2025 | 2024 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 0 | 976,131 | 105,850 | 3,762,693 |
| Friday, April 26th, 2024 | 2023 | Sandra Gardiner Interim Chief Financial Officer | 0 | 0 | 0 | 0 | 376,300 | 376,300 |
| Friday, April 26th, 2024 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| Friday, April 26th, 2024 | 2022 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 1,325,673 | 253,256 | 289,625 | 4,350,480 |
| Friday, April 26th, 2024 | 2021 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| Friday, April 26th, 2024 | 2023 | Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer | 355,760 | 0 | 0 | 0 | 883,999 | 1,239,759 |
| Friday, April 26th, 2024 | 2023 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 0 | 400,989 | 490,585 | 1,773,364 |
| Friday, April 26th, 2024 | 2022 | Jillian B. Thomsen Former Chief Financial Officer and Chief Accounting Officer | 522,200 | 0 | 1,629,478 | 198,000 | 22,645 | 4,558,317 |
| Friday, April 26th, 2024 | 2023 | Mark A. Wilson Chief Legal Officer | 540,000 | 0 | 0 | 307,800 | 20,878 | 1,100,468 |
| Friday, April 26th, 2024 | 2022 | Mark A. Wilson Chief Legal Officer | 527,500 | 0 | 1,629,478 | 194,400 | 28,093 | 4,565,465 |
| Friday, April 26th, 2024 | 2021 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| Friday, April 26th, 2024 | 2023 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 0 | 1,030,361 | 93,465 | 3,135,576 |
| Friday, April 26th, 2024 | 2022 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 4,032,255 | 650,754 | 98,821 | 11,275,830 |
| Friday, April 28th, 2023 | 2020 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| Friday, April 28th, 2023 | 2020 | John Northcott Former Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| Friday, April 28th, 2023 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| Friday, April 28th, 2023 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,149 |
| Friday, April 28th, 2023 | 2021 | Mark A. Wilson Chief Legal Officer | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| Friday, April 28th, 2023 | 2022 | Howard W. Robin President and Chief Executive Officer | 1,084,590 | 0 | 4,032,225 | 650,754 | 98,821 | 11,275,830 |
| Friday, April 28th, 2023 | 2022 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 703,490 | 0 | 1,325,673 | 253,256 | 289,625 | 4,350,480 |
| Friday, April 28th, 2023 | 2021 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| Friday, April 28th, 2023 | 2020 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| Friday, April 28th, 2023 | 2022 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 576,733 | 0 | 0 | 0 | 10,972 | 587,705 |
| Friday, April 28th, 2023 | 2022 | Jillian B. Thomsen Chief Financial Officer and Chief Accounting Officer | 522,200 | 0 | 1,629,478 | 198,000 | 22,645 | 4,558,317 |
| Friday, April 28th, 2023 | 2022 | Mark A. Wilson Chief Legal Officer | 527,500 | 0 | 1,629,478 | 194,400 | 28,093 | 4,565,465 |
| Friday, April 28th, 2023 | 2021 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,391,094 | 679,650 | 23,314 | 5,279,556 |
| Friday, April 28th, 2023 | 2020 | Gil M. Labrucherie Former Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| Friday, April 28th, 2023 | 2022 | John Northcott Former Chief Commercial Officer | 441,662 | 0 | 0 | 0 | 923,019 | 1,364,681 |
| Friday, April 28th, 2023 | 2021 | John Northcott Former Chief Commercial Officer | 675,000 | 0 | 1,707,078 | 388,125 | 7,950 | 3,776,473 |
| Friday, April 29th, 2022 | 2021 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,707,078 | 388,125 | 7,950 | 3,776,473 |
| Friday, April 29th, 2022 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| Friday, April 29th, 2022 | 2020 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| Friday, April 29th, 2022 | 2021 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,391,094 | 679,650 | 23,314 | 5,279,556 |
| Friday, April 29th, 2022 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| Friday, April 29th, 2022 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,149 |
| Friday, April 29th, 2022 | 2021 | Howard W. Robin President and Chief Executive Officer | 1,053,000 | 0 | 5,691,794 | 1,000,350 | 81,980 | 11,153,616 |
| Friday, April 29th, 2022 | 2020 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| Friday, April 29th, 2022 | 2020 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| Friday, April 29th, 2022 | 2020 | Mark A. Wilson Senior Vice President and General Counsel | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| Friday, April 29th, 2022 | 2021 | Mark A. Wilson Senior Vice President and General Counsel | 500,000 | 0 | 1,707,078 | 287,500 | 10,763 | 3,503,661 |
| Friday, April 29th, 2022 | 2019 | John Northcott Senior Vice President and Chief Commercial Officer | 56,250 | 200,000 | 3,895,980 | 0 | 23,313 | 6,365,023 |
| Friday, April 29th, 2022 | 2019 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,097 |
| Friday, April 29th, 2022 | 2021 | Jonathan Zalevsky, Ph.D. Senior Vice President and Chief Research and Development Officer | 683,000 | 0 | 2,391,094 | 471,270 | 8,385 | 4,951,247 |
| Friday, April 30th, 2021 | 2020 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 788,000 | 0 | 2,247,676 | 721,000 | 27,574 | 5,285,922 |
| Friday, April 30th, 2021 | 2020 | Howard W. Robin President and Chief Executive Officer | 1,053,400 | 0 | 4,996,266 | 1,092,000 | 95,775 | 11,241,549 |
| Friday, April 30th, 2021 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| Friday, April 30th, 2021 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| Friday, April 30th, 2021 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| Friday, April 30th, 2021 | 2020 | John Northcott Senior Vice President and Chief Commercial Officer | 675,000 | 0 | 1,604,292 | 364,500 | 117,884 | 3,832,798 |
| Friday, April 30th, 2021 | 2019 | John Northcott Senior Vice President and Chief Commercial Officer | 56,250 | 200,000 | 3,895,980 | 0 | 23,313 | 6,355,023 |
| Friday, April 30th, 2021 | 2018 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| Friday, April 30th, 2021 | 2020 | Mark A. Wilson Senior Vice President and General Counsel | 500,000 | 0 | 1,604,292 | 270,000 | 10,492 | 3,455,906 |
| Friday, April 30th, 2021 | 2020 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 683,000 | 0 | 2,247,676 | 500,000 | 9,149 | 4,941,497 |
| Friday, April 30th, 2021 | 2019 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,153 |
| Wednesday, April 29th, 2020 | 2018 | Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer | 435,000 | 0 | 4,461,658 | 424,100 | 13,347 | 6,233,595 |
| Wednesday, April 29th, 2020 | 2019 | Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer | 457,000 | 0 | 649,340 | 0 | 13,787 | 1,916,084 |
| Wednesday, April 29th, 2020 | 2017 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| Wednesday, April 29th, 2020 | 2018 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| Wednesday, April 29th, 2020 | 2019 | Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer | 683,325 | 0 | 3,131,971 | 0 | 12,498 | 7,488,841 |
| Wednesday, April 29th, 2020 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| Wednesday, April 29th, 2020 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| Wednesday, April 29th, 2020 | 2019 | Howard W. Robin President and Chief Executive Officer | 1,017,400 | 0 | 4,100,860 | 0 | 168,925 | 9,939,250 |
| Wednesday, April 29th, 2020 | 2019 | Jonathan Zalevsky, Ph.D. Chief Research and Development Officer | 582,000 | 0 | 3,131,971 | 0 | 8,120 | 7,274,153 |
| Wednesday, April 29th, 2020 | 2019 | John Northcott Senior Vice President and Chief Commercial Officer | 56,250 | 200,000 | 3,895,980 | 0 | 13,313 | 6,355,023 |
| Tuesday, April 30th, 2019 | 2018 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 600,000 | 0 | 1,748,824 | 480,000 | 17,556 | 4,811,856 |
| Tuesday, April 30th, 2019 | 2018 | Jillian B. Thomsen Senior Vice President Finance and Chief Accounting Officer | 435,000 | 0 | 4,461,657 | 424,100 | 13,347 | 6,233,595 |
| Tuesday, April 30th, 2019 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| Tuesday, April 30th, 2019 | 2018 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 489,417 | 0 | 1,350,866 | 464,900 | 17,513 | 3,839,442 |
| Tuesday, April 30th, 2019 | 2017 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 529,084 | 0 | 2,958,794 | 525,000 | 13,988 | 7,698,950 |
| Tuesday, April 30th, 2019 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| Tuesday, April 30th, 2019 | 2017 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 471,500 | 0 | 1,706,998 | 353,625 | 15,394 | 4,666,027 |
| Tuesday, April 30th, 2019 | 2018 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 631,696 | 0 | 2,099,320 | 631,600 | 11,930 | 5,733,928 |
| Tuesday, April 30th, 2019 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| Tuesday, April 30th, 2019 | 2018 | Howard W. Robin President and Chief Executive Officer | 968,921 | 0 | 4,998,206 | 1,647,100 | 98,184 | 13,330,667 |
| Tuesday, April 30th, 2019 | 2016 | Stephen K. Doberstein, Ph.D. Chief Research and Development Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| Tuesday, April 30th, 2019 | 2017 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| Tuesday, April 30th, 2019 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| Monday, April 30th, 2018 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| Monday, April 30th, 2018 | 2017 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 471,500 | 0 | 1,706,998 | 353,625 | 15,394 | 4,666,027 |
| Monday, April 30th, 2018 | 2017 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 607,400 | 0 | 2,958,794 | 531,475 | 10,338 | 7,780,091 |
| Monday, April 30th, 2018 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| Monday, April 30th, 2018 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| Monday, April 30th, 2018 | 2017 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 529,084 | 0 | 2,958,794 | 525,000 | 13,988 | 7,698,950 |
| Monday, April 30th, 2018 | 2015 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| Monday, April 30th, 2018 | 2016 | John Nicholson Senior Vice President and Chief Operating Officer | 599,833 | 0 | 489,596 | 367,200 | 14,995 | 2,774,744 |
| Monday, April 30th, 2018 | 2017 | John Nicholson Senior Vice President and Chief Operating Officer | 625,800 | 0 | 2,958,794 | 547,575 | 26,907 | 7,831,160 |
| Monday, April 30th, 2018 | 2015 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 430,600 | 0 | 808,595 | 204,500 | 14,815 | 1,778,038 |
| Monday, April 30th, 2018 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| Monday, April 30th, 2018 | 2015 | John Nicholson Senior Vice President and Chief Operating Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| Monday, April 30th, 2018 | 2015 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 495,800 | 0 | 326,548 | 198,300 | 13,054 | 1,161,287 |
| Monday, April 30th, 2018 | 2016 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Research and Development Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| Monday, April 30th, 2018 | 2017 | Howard W. Robin President and Chief Executive Officer | 940,700 | 0 | 6,884,888 | 1,599,190 | 127,975 | 18,097,411 |
| Monday, May 1st, 2017 | 2015 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| Monday, May 1st, 2017 | 2016 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 582,167 | 0 | 489,596 | 356,400 | 8,653 | 2,739,936 |
| Monday, May 1st, 2017 | 2016 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 447,800 | 0 | 367,197 | 279,875 | 14,454 | 1,541,776 |
| Monday, May 1st, 2017 | 2014 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| Monday, May 1st, 2017 | 2015 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 621,000 | 0 | 466,498 | 279,500 | 6,657 | 1,555,205 |
| Monday, May 1st, 2017 | 2014 | John Nicholson Senior Vice President and Chief Operating Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| Monday, May 1st, 2017 | 2016 | John Nicholson Senior Vice President and Chief Operating Officer | 599,833 | 0 | 489,596 | 367,200 | 14,995 | 2,774,744 |
| Monday, May 1st, 2017 | 2015 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 430,600 | 0 | 808,595 | 204,500 | 14,815 | 1,778,038 |
| Monday, May 1st, 2017 | 2015 | John Nicholson Senior Vice President and Chief Operating Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| Monday, May 1st, 2017 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,278 | 8,032,982 |
| Monday, May 1st, 2017 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| Monday, May 1st, 2017 | 2016 | Howard W. Robin President and Chief Executive Officer | 920,000 | 0 | 1,346,390 | 897,000 | 15,103 | 4,764,143 |
| Monday, May 1st, 2017 | 2016 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 639,600 | 0 | 489,596 | 335,790 | 9,837 | 2,617,883 |
| Monday, May 1st, 2017 | 2016 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 508,200 | 0 | 428,396 | 266,805 | 12,806 | 1,720,733 |
| Monday, May 1st, 2017 | 2014 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 477,583 | 0 | 0 | 311,350 | 11,804 | 2,139,128 |
| Monday, May 1st, 2017 | 2014 | Gil M. Labrucherie Senior Vice President and Chief Financial Officer | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| Monday, May 1st, 2017 | 2015 | Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer | 495,800 | 0 | 326,548 | 198,300 | 13,054 | 1,161,287 |
| Friday, April 29th, 2016 | 2013 | Howard W. Robin President and Chief Executive Officer | 831,247 | 0 | 0 | 656,200 | 15,040 | 3,569,652 |
| Friday, April 29th, 2016 | 2013 | John Nicholson Senior Vice President and Chief Financial Officer | 524,264 | 0 | 0 | 276,000 | 12,112 | 1,662,210 |
| Friday, April 29th, 2016 | 2014 | John Nicholson Senior Vice President and Chief Financial Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| Friday, April 29th, 2016 | 2015 | John Nicholson Senior Vice President and Chief Financial Officer | 563,100 | 0 | 808,594 | 267,500 | 12,661 | 1,971,383 |
| Friday, April 29th, 2016 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,278 | 8,032,982 |
| Friday, April 29th, 2016 | 2015 | Howard W. Robin President and Chief Executive Officer | 892,620 | 0 | 2,099,236 | 625,000 | 12,156 | 4,445,988 |
| Friday, April 29th, 2016 | 2013 | Gil M. Labrucherie Senior Vice President and General Counsel | 504,195 | 0 | 0 | 278,000 | 7,238 | 1,478,488 |
| Friday, April 29th, 2016 | 2014 | Gil M. Labrucherie Senior Vice President and General Counsel | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| Friday, April 29th, 2016 | 2015 | Maninder Hora, Ph.D. Senior Vice President Pharmaceutical Development and Manufacturing Operations | 430,600 | 0 | 808,594 | 204,500 | 14,815 | 1,778,037 |
| Friday, April 29th, 2016 | 2015 | Gil M. Labrucherie Senior Vice President and General Counsel | 546,500 | 0 | 808,594 | 259,600 | 9,562 | 1,943,784 |
| Friday, April 29th, 2016 | 2014 | Ivan P. Gergel Senior Vice President and | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| Friday, April 29th, 2016 | 2015 | Ivan P. Gergel Senior Vice President and | 621,000 | 0 | 466,498 | 279,500 | 6,657 | 1,555,205 |
| Thursday, April 30th, 2015 | 2013 | John Nicholson Senior Vice President and Chief Financial Officer | 524,264 | 0 | 0 | 276,000 | 12,112 | 1,662,210 |
| Thursday, April 30th, 2015 | 2012 | Howard W. Robin President and Chief Executive Officer | 807,196 | 500 | 0 | 910,125 | 14,351 | 3,242,332 |
| Thursday, April 30th, 2015 | 2012 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 433,605 | 0 | 0 | 260,000 | 9,613 | 1,080,758 |
| Thursday, April 30th, 2015 | 2012 | Gil M. Labrucherie Senior Vice President and General Counsel | 488,270 | 0 | 0 | 330,000 | 6,503 | 1,391,083 |
| Thursday, April 30th, 2015 | 2014 | Gil M. Labrucherie Senior Vice President and General Counsel | 526,125 | 0 | 0 | 396,000 | 8,354 | 3,242,858 |
| Thursday, April 30th, 2015 | 2012 | John Nicholson Senior Vice President and Chief Financial Officer | 509,529 | 500 | 0 | 357,000 | 12,225 | 1,256,794 |
| Thursday, April 30th, 2015 | 2014 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 477,583 | 0 | 0 | 311,350 | 11,804 | 2,139,128 |
| Thursday, April 30th, 2015 | 2013 | Howard W. Robin President and Chief Executive Officer | 831,247 | 0 | 0 | 656,200 | 15,039 | 3,569,652 |
| Thursday, April 30th, 2015 | 2013 | Gil M. Labrucherie Senior Vice President and General Counsel | 504,195 | 0 | 0 | 278,000 | 7,238 | 1,478,488 |
| Thursday, April 30th, 2015 | 2013 | Stephen K. Doberstein Senior Vice President and Chief Scientific Officer | 459,722 | 0 | 0 | 231,000 | 9,513 | 1,159,605 |
| Thursday, April 30th, 2015 | 2014 | Howard W. Robin President and Chief Executive Officer | 860,004 | 0 | 0 | 1,131,945 | 18,279 | 8,032,982 |
| Thursday, April 30th, 2015 | 2014 | John Nicholson Senior Vice President and Chief Financial Officer | 542,458 | 0 | 0 | 408,000 | 12,854 | 3,305,495 |
| Thursday, April 30th, 2015 | 2014 | Ivan P. Gergel , M.D. Senior Vice President and Chief Medical Officer | 372,728 | 0 | 0 | 227,500 | 2,133 | 4,213,251 |
| Wednesday, April 30th, 2014 | 2013 | Name and Position | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 30th, 2013 | 2011 | Howard W. Robin President and Chief Executive Officer | 785,131 | 0 | 0 | 650,000 | 14,973 | 3,182,634 |
| Tuesday, April 30th, 2013 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| Tuesday, April 30th, 2013 | 2012 | Howard W. Robin President and Chief Executive Officer | 807,196 | 500 | 0 | 910,125 | 18,334 | 3,246,314 |
| Monday, April 30th, 2012 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| Monday, April 30th, 2012 | 2009 | Howard W. Robin President and Chief Executive Officer | 730,417 | 0 | 0 | 1,000,000 | 14,973 | 3,003,133 |
| Monday, April 30th, 2012 | 2011 | Howard W. Robin President and Chief Executive Officer | 785,131 | 0 | 0 | 650,000 | 14,973 | 3,182,634 |
| Friday, April 29th, 2011 | 2008 | Gil M. Labrucherie Senior Vice President and General Counsel | 380,098 | 100,000 | 0 | 381,900 | 9,409 | 1,080,161 |
| Friday, April 29th, 2011 | 2010 | Gil M. Labrucherie Senior Vice President and General Counsel | 434,250 | 500 | 0 | 294,300 | 13,272 | 1,466,871 |
| Friday, April 29th, 2011 | 2008 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 442,531 | 0 | 0 | 388,610 | 108,600 | 1,193,228 |
| Friday, April 29th, 2011 | 2009 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 459,594 | 0 | 0 | 403,500 | 51,198 | 1,835,959 |
| Friday, April 29th, 2011 | 2010 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 478,417 | 0 | 0 | 288,000 | 15,330 | 1,506,295 |
| Friday, April 29th, 2011 | 2008 | Howard W. Robin President and Chief Executive Officer | 680,000 | 0 | 0 | 618,800 | 14,586 | 2,506,266 |
| Friday, April 29th, 2011 | 2009 | Gil M. Labrucherie Senior Vice President and General Counsel | 412,242 | 0 | 0 | 363,500 | 13,063 | 1,795,052 |
| Friday, April 29th, 2011 | 2010 | Howard W. Robin President and Chief Executive Officer | 758,581 | 0 | 0 | 700,000 | 14,973 | 4,492,504 |
| Friday, April 29th, 2011 | 2009 | Howard W. Robin President and Chief Executive Officer | 730,417 | 0 | 0 | 1,000,000 | 14,973 | 3,003,133 |
| Friday, April 29th, 2011 | 2010 | Rinko Ghosh Senior Vice President and Chief Business Officer | 397,739 | 0 | 0 | 276,750 | 8,009 | 2,215,826 |
| Friday, April 29th, 2011 | 2010 | Stephen K. Doberstein Ph.D. Senior Vice President and Chief Scientific Officer | 395,455 | 150,000 | 0 | 240,000 | 7,818 | 3,533,340 |
| Friday, April 30th, 2010 | 2009 | Name and Position | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, April 29th, 2009 | 2007 | Howard W. Robin President and Chief Executive Officer | 654,243 | 0 | 0 | 601,800 | 4,083 | 2,227,770 |
| Wednesday, April 29th, 2009 | 2008 | Howard W. Robin President and Chief Executive Officer | 680,000 | 0 | 0 | 618,800 | 14,586 | 2,149,092 |
| Wednesday, April 29th, 2009 | 2008 | Gil M. Labrucherie Senior Vice President and General Counsel | 380,098 | 100,000 | 10,668 | 381,900 | 9,409 | 1,175,975 |
| Wednesday, April 29th, 2009 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| Wednesday, April 29th, 2009 | 2008 | Bharatt M. Chowrira | 295,076 | 80,485 | 0 | 427,500 | 4,386 | 951,161 |
| Wednesday, April 29th, 2009 | 2007 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 104,641 | 0 | 1,055 | 82,300 | 31,185 | 273,470 |
| Wednesday, April 29th, 2009 | 2008 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 442,531 | 0 | 18,190 | 388,610 | 108,600 | 1,309,797 |
| Wednesday, April 29th, 2009 | 2007 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 372,638 | 0 | 0 | 282,800 | 2,886 | 933,064 |
| Wednesday, April 29th, 2009 | 2008 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 438,739 | 250,000 | 0 | 0 | 653,666 | 1,949,881 |
| Tuesday, April 29th, 2008 | 2007 | Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer | 252,399 | 0 | 0 | 64,772 | 404,367 | 881,418 |
| Tuesday, April 29th, 2008 | 2007 | John Nicholson Senior Vice President, Finance and Chief Financial Officer | 104,641 | 0 | 1,055 | 82,300 | 31,185 | 273,470 |
| Tuesday, April 29th, 2008 | 2007 | Howard W. Robin President and Chief Executive Officer | 654,243 | 0 | 0 | 601,800 | 4,083 | 2,227,770 |
| Tuesday, April 29th, 2008 | 2006 | David Johnston Former Senior Vice President Research and Development | 335,910 | 0 | 71,157 | 119,574 | 9,759 | 701,947 |
| Tuesday, April 29th, 2008 | 2007 | David Johnston Former Senior Vice President Research and Development | 390,831 | 42,028 | 18,266 | 71,248 | 528,870 | 1,179,043 |
| Tuesday, April 29th, 2008 | 2007 | John S. Patton, Ph.D. Chief Research Fellow | 303,214 | 86,256 | 70,875 | 164,500 | 33,833 | 833,217 |
| Tuesday, April 29th, 2008 | 2007 | Hoyoung Huh M.D., Ph.D. Chief Operating Officer and Head of the PEGylation Business Unit | 451,153 | 20,000 | 0 | 344,000 | 9,182 | 1,231,782 |
| Tuesday, April 29th, 2008 | 2006 | Louis Drapeau Former Senior Vice President, Finance and Chief Financial Officer | 336,589 | 0 | 0 | 119,968 | 11,355 | 669,371 |
| Tuesday, April 29th, 2008 | 2006 | Robert B. Chess Former Acting President and Chief Executive Officer | 418,459 | 0 | 716,224 | 262,718 | 8,040 | 2,417,150 |
| Tuesday, April 29th, 2008 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| Tuesday, April 29th, 2008 | 2006 | John S. Patton, Ph.D. Chief Research Fellow | 286,534 | 0 | 292,289 | 131,060 | 9,071 | 822,366 |
| Tuesday, April 29th, 2008 | 2007 | Timothy Harkness Former Senior Vice President, Finance and Chief Financial Officer | 141,094 | 0 | 6,581 | 0 | 739,445 | 937,166 |
| Tuesday, April 29th, 2008 | 2007 | Robert B. Chess Former Acting President and Chief Executive Officer | 100,000 | 317,000 | 339,753 | 0 | 8,734 | 1,468,751 |
| Tuesday, April 29th, 2008 | 2007 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 372,638 | 0 | 0 | 282,800 | 2,886 | 933,064 |
| Wednesday, April 25th, 2007 | 2006 | Ajay Bansal Senior Vice President of Finance and Chief Financial Officer | 74,142 | 0 | 349,059 | 25,048 | 457,258 | 1,252,073 |
| Wednesday, April 25th, 2007 | 2006 | Robert B. Chess Acting President and Chief Executive Officer | 418,459 | 0 | 716,224 | 262,718 | 8,040 | 2,417,150 |
| Wednesday, April 25th, 2007 | 2006 | John S. Patton, Ph.D. Chief Scientific Officer | 286,534 | 0 | 292,289 | 131,060 | 9,071 | 822,397 |
| Wednesday, April 25th, 2007 | 2006 | Nevan C. Elam Senior Vice President and Head of the Pulmonary Business Unit | 321,332 | 0 | 35,911 | 114,804 | 582 | 649,598 |
| Wednesday, April 25th, 2007 | 2006 | Louis Drapeau Senior Vice President, Finance and Chief Financial Officer | 336,589 | 0 | 0 | 119,968 | 11,355 | 669,372 |
| Wednesday, April 25th, 2007 | 2006 | David Johnston Senior Vice President Research and Development | 335,910 | 0 | 71,157 | 119,574 | 9,759 | 701,947 |
| Wednesday, April 25th, 2007 | 2006 | Ajit S. Gill President and Chief Executive Officer | 285,371 | 0 | 1,388,172 | 148,994 | 1,700,877 | 12,312,868 |
| Tuesday, April 18th, 2006 | 2004 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 261,354 | 127,105 | 476,250 | 0 | 6,740 | 871,449 |
| Tuesday, April 18th, 2006 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| Tuesday, April 18th, 2006 | 2005 | David Johnston Senior Vice President Research Development | 314,246 | 129,253 | 184,500 | 0 | 9,261 | 637,260 |
| Tuesday, April 18th, 2006 | 2004 | David Johnston Senior Vice President Research Development | 300,000 | 83,500 | 0 | 0 | 7,542 | 391,042 |
| Tuesday, April 18th, 2006 | 2003 | David Johnston Senior Vice President Research Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuesday, April 18th, 2006 | 2005 | Ajit S. Gill Chief Executive Officer, President and Director | 510,833 | 262,786 | 904,000 | 0 | 11,113 | 1,688,732 |
| Tuesday, April 18th, 2006 | 2004 | Ajit S. Gill Chief Executive Officer, President and Director | 498,049 | 272,289 | 977,500 | 0 | 10,278 | 1,758,116 |
| Tuesday, April 18th, 2006 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| Tuesday, April 18th, 2006 | 2005 | Robert B. Chess Executive Chairman | 135,805 | 80,892 | 0 | 0 | 8,425 | 225,122 |
| Tuesday, April 18th, 2006 | 2004 | Robert B. Chess Executive Chairman | 167,019 | 93,603 | 325,820 | 0 | 7,435 | 593,877 |
| Tuesday, April 18th, 2006 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| Tuesday, April 18th, 2006 | 2005 | Ajay Bansal Chief Financial Officer | 307,824 | 122,832 | 185,400 | 0 | 3,824 | 619,880 |
| Tuesday, April 18th, 2006 | 2004 | Ajay Bansal Chief Financial Officer | 288,650 | 105,188 | 476,250 | 0 | 6,995 | 877,083 |
| Tuesday, April 18th, 2006 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| Tuesday, April 18th, 2006 | 2005 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 274,583 | 142,735 | 184,500 | 0 | 7,793 | 609,611 |
| Thursday, April 14th, 2005 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| Thursday, April 14th, 2005 | 2004 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 342,405 | 153,629 | 0 | 0 | 11,094 | 507,128 |
| Thursday, April 14th, 2005 | 2002 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| Thursday, April 14th, 2005 | 2003 | J. Milton Harris, Ph.D. Chief Scientific Officer, Nektar Therapeutics AL, Corporation | 321,000 | 110,662 | 0 | 0 | 7,980 | 439,642 |
| Thursday, April 14th, 2005 | 2004 | Ajit S. Gill Chief Executive Officer, President and Director | 498,049 | 272,289 | 977,500 | 0 | 10,278 | 1,758,116 |
| Thursday, April 14th, 2005 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| Thursday, April 14th, 2005 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| Thursday, April 14th, 2005 | 2004 | Robert B. Chess Executive Chairman | 167,019 | 93,603 | 325,820 | 0 | 7,435 | 593,877 |
| Thursday, April 14th, 2005 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| Thursday, April 14th, 2005 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| Thursday, April 14th, 2005 | 2004 | Ajay Bansal Chief Financial Officer | 288,650 | 105,188 | 476,250 | 0 | 6,995 | 877,083 |
| Thursday, April 14th, 2005 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| Thursday, April 14th, 2005 | 2002 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 14th, 2005 | 2004 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 261,354 | 127,105 | 476,250 | 0 | 6,740 | 871,449 |
| Thursday, April 14th, 2005 | 2003 | David Johnston Senior Vice President Research Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 14th, 2005 | 2002 | David Johnston Senior Vice President Research Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 14th, 2005 | 2004 | David Johnston Senior Vice President Research Development | 300,000 | 83,500 | 0 | 0 | 7,542 | 391,042 |
| Thursday, April 14th, 2005 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| Thursday, April 29th, 2004 | 2003 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 321,000 | 110,662 | 0 | 0 | 7,980 | 439,642 |
| Thursday, April 29th, 2004 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| Thursday, April 29th, 2004 | 2003 | Robert B. Chess Executive Chairman | 183,641 | 115,337 | 0 | 0 | 6,559 | 305,537 |
| Thursday, April 29th, 2004 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
| Thursday, April 29th, 2004 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| Thursday, April 29th, 2004 | 2003 | Ajit S. Gill Chief Executive Officer, President and Director | 474,461 | 250,903 | 0 | 0 | 9,968 | 735,332 |
| Thursday, April 29th, 2004 | 2002 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| Thursday, April 29th, 2004 | 2003 | Ajay Bansal Chief Financial Officer | 235,308 | 170,067 | 0 | 0 | 4,726 | 410,101 |
| Thursday, April 29th, 2004 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| Thursday, April 29th, 2004 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| Thursday, April 29th, 2004 | 2003 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 248,908 | 112,822 | 0 | 0 | 8,270 | 370,000 |
| Thursday, April 29th, 2004 | 2001 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| Thursday, April 29th, 2004 | 2001 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 29th, 2004 | 2002 | Ajay Bansal Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 29th, 2004 | 2001 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 156,000 | 0 | 0 | 0 | 450 | 156,450 |
| Monday, April 28th, 2003 | 2001 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 156,000 | 0 | 0 | 0 | 450 | 156,450 |
| Monday, April 28th, 2003 | 2002 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 307,500 | 68,402 | 0 | 0 | 6,694 | 382,596 |
| Monday, April 28th, 2003 | 2001 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 61,894 | 25,000 | 0 | 0 | 158 | 87,052 |
| Monday, April 28th, 2003 | 2000 | Douglas H. Altschuler Former Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| Monday, April 28th, 2003 | 2000 | Ajit S. Gill Chief Executive Officer, President and Director | 387,788 | 746,546 | 0 | 0 | 6,066 | 1,140,400 |
| Monday, April 28th, 2003 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
| Monday, April 28th, 2003 | 2002 | Ajit S. Gill Chief Executive Officer, President and Director | 451,206 | 201,442 | 0 | 0 | 7,173 | 659,821 |
| Monday, April 28th, 2003 | 2002 | Robert B. Chess Executive Chairman | 251,722 | 117,183 | 0 | 0 | 6,628 | 375,533 |
| Monday, April 28th, 2003 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| Monday, April 28th, 2003 | 2000 | Robert B. Chess Executive Chairman | 251,250 | 668,945 | 0 | 0 | 5,520 | 925,715 |
| Monday, April 28th, 2003 | 2002 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 373,060 | 71,458 | 0 | 0 | 9,095 | 453,613 |
| Monday, April 28th, 2003 | 2001 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Monday, April 28th, 2003 | 2000 | Arnold J. Repta, Ph.D. Vice President, Research and Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Monday, April 28th, 2003 | 2002 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 236,833 | 90,921 | 0 | 0 | 7,871 | 335,625 |
| Monday, April 28th, 2003 | 2001 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| Monday, April 28th, 2003 | 2002 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 324,000 | 186,977 | 0 | 0 | 7,480 | 518,457 |
| Monday, April 28th, 2003 | 2000 | John S. Patton, Ph.D. Founder, Chief Scientific Officer and Director | 209,271 | 92,369 | 0 | 0 | 1,659 | 303,299 |
| Monday, April 28th, 2003 | 2000 | J. Milton Harris, Ph.D. President, Nektar Therapeutics AL, Corporation | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, May 15th, 2002 | 2000 | Ajit S. Gill Chief Executive Officer, President and Director | 387,788 | 746,546 | 0 | 0 | 6,066 | 1,140,400 |
| Wednesday, May 15th, 2002 | 1999 | John S. Patton Founder, Chief Scientific Officer and Director | 190,774 | 76,518 | 0 | 0 | 6,117 | 273,409 |
| Wednesday, May 15th, 2002 | 1999 | Stephen L. Hurst Vice President, Human Resources | 179,316 | 57,605 | 0 | 0 | 1,186 | 238,107 |
| Wednesday, May 15th, 2002 | 2000 | Stephen L. Hurst Vice President, Human Resources | 171,863 | 96,044 | 0 | 0 | 3,427 | 271,334 |
| Wednesday, May 15th, 2002 | 2001 | Stephen L. Hurst Vice President, Human Resources | 129,050 | 54,234 | 0 | 0 | 4,498 | 187,782 |
| Wednesday, May 15th, 2002 | 1999 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, May 15th, 2002 | 2000 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| Wednesday, May 15th, 2002 | 2001 | Douglas H. Altschuler Vice President, General Counsel and Secretary | 61,894 | 25,000 | 0 | 0 | 158 | 87,052 |
| Wednesday, May 15th, 2002 | 2000 | John S. Patton Founder, Chief Scientific Officer and Director | 209,271 | 92,369 | 0 | 0 | 1,659 | 303,299 |
| Wednesday, May 15th, 2002 | 2001 | John S. Patton Founder, Chief Scientific Officer and Director | 222,833 | 90,125 | 0 | 0 | 6,906 | 319,864 |
| Wednesday, May 15th, 2002 | 1999 | Robert B. Chess Executive Chairman | 248,013 | 113,249 | 0 | 0 | 6,005 | 367,267 |
| Wednesday, May 15th, 2002 | 2000 | Robert B. Chess Executive Chairman | 251,250 | 668,945 | 0 | 0 | 5,520 | 925,715 |
| Wednesday, May 15th, 2002 | 1999 | Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary | 87,739 | 30,000 | 0 | 0 | 175 | 117,914 |
| Wednesday, May 15th, 2002 | 2001 | Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary | 219,313 | 68,911 | 0 | 0 | 5,730 | 293,954 |
| Wednesday, May 15th, 2002 | 2000 | Brigid A. Makes Vice President, Finance Administration, Chief Financial Officer and Assistant Secretary | 205,750 | 70,636 | 0 | 0 | 5,730 | 282,116 |
| Wednesday, May 15th, 2002 | 2001 | Robert B. Chess Executive Chairman | 254,138 | 121,270 | 0 | 0 | 5,520 | 380,928 |
| Wednesday, May 15th, 2002 | 1999 | Ajit S. Gill Chief Executive Officer, President and Director | 248,013 | 113,249 | 0 | 0 | 6,452 | 367,714 |
| Wednesday, May 15th, 2002 | 2001 | Ajit S. Gill Chief Executive Officer, President and Director | 422,100 | 201,135 | 0 | 0 | 6,066 | 629,301 |
